We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
Attruby will be available at a recommended dose of 712 mg, taken twice daily, at a list price of $18,759.12 for a 28-day ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Zacks.com on MSN23h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the ...
Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...
Lockheed Martin has felt financial strain as early funding for the upcoming F-35 jets dried up, but kept working on them to avoid supply chain disruptions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback